

Review Form 1.7

Journal Name:	International Research Journal of Oncology
Manuscript Number:	Ms_IRJO_107367
Title of the Manuscript:	Restoration of Chemo-surveillance as a Top Priority to Save Cancer Patients
Type of the Article	Minireview paper

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</p>	<p>The article exposes cell differentiation agent (CDA) status as a cancer drug, but it does not convince by its fault of evidences. The clinical research progress of urine polyacid peptide injection is absent from this submission.</p> <p>Maybe</p> <p>The abstract is twice the number of words permitted by the instructions for authors.</p> <p>Maybe</p> <p>The structure of key epigenetic machinery illustrates the successes of epigenetic drugs in the treatment of myelodysplastic syndrome (MDS). This is to say that as a guiding role in the research, the idea vehiculated by this submission is its involvement in the diagnostic and treatment of MDS; but the submitted content is far from free to open out completely. Concerning CDA-II, the minireview does not offer:</p> <ul style="list-style-type: none"> - an approach to the differential proteins and related molecular mechanisms of CDA-II - IM resistance CML patients - miR-124/MAPK1 - the effect of urinary polyacid peptide on anemia improvement in patients <p>References for the sentence "According to Professor Jun Ma, Director of Harbin Institute of Hematology and Oncology ... were no longer dependent on blood transfusion to stay healthy." should be cited.</p>	
<p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>		
<p>Optional/General comments</p>	<p>Ortographic mistake: 35: change "ETC2-dependent rRNA synthesis is required for KRS-TRP53-driven lung adenocaecinoma" to "Ect2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma"</p>	

[Review Form 1.7](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Enrique Wulff
Department, University & Country	ICMAN-CSIC, Spain